Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SL-325 · 2 trials · 2 indications
The proportion of participants who achieve endoscopic response, as defined by a ≥50% decrease in Simplified Endoscopic Score for Crohn's disease (SES-CD) from baseline.
Incidence and severity of treatment-emergent adverse events
| Arm | Type | Description |
|---|---|---|
| SL-325 high dose | EXPERIMENTAL | - |
| SL-325 mid dose | EXPERIMENTAL | - |
| SL-325 low dose | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| SAD: SL-325 | EXPERIMENTAL | Participants will receive a single dose of SL-325 in escalating dose cohorts |
| SAD: Placebo | PLACEBO_COMPARATOR | Participants will receive a single dose of placebo (normal saline) |
| MAD: SL-325 | EXPERIMENTAL | Participants will receive a three doses of SL-325 in escalating dose cohorts |
| MAD: Placebo | PLACEBO_COMPARATOR | Participants will receive a three doses of placebo (normal saline) |
| Name | Type | Description |
|---|---|---|
| SL-325 | DRUG | SL-325 administered intravenously |
| Placebo | DRUG | Placebo administered intravenously |
| Placebo (Normal Saline) | OTHER | Normal saline |
Key Inclusion Criteria: * A diagnosis of Crohn's disease confirmed by endoscopy and histopathology ≥ 3 months prior to Screening * Moderately to severely active CD as defined by CDAI of ≥ 220 and ≤ 450 * SES-CD score ≥ 6 if ileocolonic or colonic disease, or ≥ 4 if isolated ileal disease, as assess...
Top 11 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 6 | PHASE3 | Duvakitug, SAR441566, balinatunfib, SAR442970 |
| Eli Lilly and Company | LLY | 8 | PHASE3 | Mirikizumab, Tirzepatide, MORF-057, LY4395089 |
| AbbVie, Inc. | ABBV | 14 | PHASE3 | Risankizumab, Upadacitinib, Lutikizumab, Trosunilimab, ABBV-8736 |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 16 | PHASE3 | Vedolizumab, Zasocitinib, Darvadstrocel |
| Johnson & Johnson | JNJ | 13 | PHASE3 | Ustekinumab, Guselkumab, Golimumab, JNJ-78934804, Icotrokinra |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Tulisokibart |
| AstraZeneca PLC | AZN | 2 | PHASE2 | AZD7798 |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY001, SPY002, SPY003 |
| Abivax SA Sponsored ADR | ABVX | 1 | PHASE2 | Obefazimod |
| Palisade Bio, Inc. | PALI | 1 | PHASE1 | PALI-2108 |
SL-325 is an investigational small molecule being developed for Crohn's Disease. It is also being studied in healthy volunteers to assess its safety and pharmacological profile. The drug is currently in clinical development and has not been approved by regulatory authorities.
SL-325 targets DR3, a protein involved in inflammatory signaling pathways. By modulating DR3 activity, the drug is intended to address the underlying inflammation associated with Crohn's Disease. This mechanism is being evaluated in clinical trials to determine its therapeutic potential.
SL-325 is being developed by Shattuck Labs, Inc., a biopharmaceutical company. The company is conducting clinical trials to evaluate the drug's safety and efficacy in healthy volunteers and patients with Crohn's Disease.
SL-325 is in Phase 2 clinical development for Crohn's Disease. A Phase 1 study in healthy volunteers is also active but not recruiting participants. The drug is investigational and has not received regulatory approval.
SL-325 is being studied in two clinical trials. NCT07158437 is a Phase 1 study in healthy volunteers in the United States. NCT07753850 is a Phase 2 study in patients with Crohn's Disease, which is not yet recruiting. Both trials enroll adults aged 18 years and older.
No, SL-325 is not the same as DR3. DR3 is the molecular target that SL-325 acts on. SL-325 is a small molecule drug designed to interact with DR3, a protein involved in inflammatory responses, to potentially treat Crohn's Disease.